Apogee Therapeutics Logo
US03770N1019
APGE

Apogee Therapeutics

Previsioni

Il prezzo obiettivo medio degli analisti è 118,39 € (+1,54%). La mediana è 123,03 € (+5,52%).

Acquista
  2
Mantieni
  12
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Apogee Therapeutics reaches record high at $134.89

    Apogee Therapeutics' stock reached a record high of $134.89, representing a year-to-date gain of 256.92%. InvestingPro notes the stock may appear overvalued at this level and that its fair-value estimate is substantially lower. Apogee has more cash than debt but was unprofitable over the past twelve months. Shareholders approved AbbVie's acquisition, which values the company at $10.9 billion ($135.11 per share) and prompted analyst downgrades and adjusted price targets. » Altro su de.investing.com


  • Apogee Therapeutics reaches record high at $134.47 ahead of takeover by AbbVie

    Apogee Therapeutics shares rose to an all-time high of $134.47 and show a year-to-date return of around 270% with a market capitalization of $10.08 billion. AbbVie announced an acquisition agreement at $135.11 per share, valuing Apogee at about $10.9 billion, while InvestingPro and RSI indicators point to overvaluation and overbought conditions. After the announcement, Mizuho and UBS downgraded the stock from buy to neutral, while RBC raised its price target to $97; Apogee also closed R&D agreements with Paragon Therapeutics and appointed new directors. » Altro su de.investing.com


  • Apogee Therapeutics sold by Baron Capital after AbbVie agrees $135.11-per-share buyout

    Baron Health Care Fund sold its position in Apogee Therapeutics following AbbVie's announced acquisition of Apogee for $135.11 per share, a 49.5% premium to the prior close. The fund cited Apogee as a key contributor to its biotechnology stock selection during Q2 and reported overall quarterly gains. Apogee shares have risen sharply over the past year and the deal values the company at roughly $10.11 billion. » Altro su finance.yahoo.com


  • Apogee Therapeutics reaches record high of $134.34

    Shares of Apogee Therapeutics rose to an all-time high of $134.34, about 243% above last year; market capitalization is roughly $10.05 billion. AbbVie announced a takeover agreement at $135.11 per share, valuing the company at about $10.9 billion, after which analysts at Mizuho and UBS downgraded the stock to "Neutral" and cited price targets around $135. Additional developments: a partnership with Paragon Therapeutics to develop an IL-31R antibody, an RBC price target of $97, and the move of zumilokibart into phase III trials. » Altro su de.investing.com


  • Apogee Therapeutics reaches record high of $133.88 after takeover agreement with AbbVie

    Apogee Therapeutics' stock rose to a record high of $133.88, bringing market capitalization to about $10.02 billion. InvestingPro rates the stock as overvalued versus its fair value and notes an overbought RSI, despite strong performance (+250% over the past year). AbbVie announced a definitive takeover agreement at $135.11 per share (around $10.9 billion), after which several analysts downgraded their ratings to neutral and set price targets near $135. Additionally, Apogee announced collaboration agreements with Paragon Therapeutics to develop antibodies against the interleukin-31 receptor, and confirmed board elections and approved shareholder proposals. » Altro su de.investing.com

Dati finanziari

Nell'ultimo trimestre, Apogee Therapeutics ha registrato ricavi pari a 0 € e un utile netto di -75,23 Mln €

(EUR) giugno 2026
YoY
Ricavi 0 -
Utile lordo 0 -
Utile netto -75,23 Mln 34,15%
EBITDA -73,42 Mln 31,86%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
7,66 Mld €
Numero di azioni
62,2 Mln
Massimo/minimo a 52 settimane
123,11 € - 32,25 €
Dividendi No
Beta
0,34
Rapporto P/E
-31,12
Rapporto PEG
6,57
Rapporto P/B
8,53
Rapporto P/S
0,00

Profilo aziendale

Apogee Therapeutics, Inc., tramite la sua controllata, opera come societa di biotecnologie che sviluppa biologici per il trattamento della dermatite atopica (AD), della broncopneumopatia cronica ostruttiva (BPCO) e di indicazioni infiammatorie e immunologiche correlate. La societa sviluppa principalmente APG777, un anticorpo monoclonale (mAb) sottocutaneo (SQ) a emivita estesa per la AD; e APG808, un mAb SQ a emivita estesa per la BPCO. I suoi programmi in fase piu precoce includono APG990, un mAb SQ a emivita estesa per il trattamento della AD; e APG222, anticorpi SQ a emivita estesa per la AD. La societa e stata fondata nel 2022 ed ha sede a Waltham, Massachusetts.

Nome
Apogee Therapeutics
CEO
Michael Thomas Henderson
Sede centrale Waltham, ma
Stati Uniti
Sito web
Industria
Prodotti alimentari
Quotazione in borsa
14/07/2023
Dipendenti 261

Simboli di borsa

Borsa Simbolo
NASDAQ
APGE
🍪

Parqet  usa i cookie. Scopri di più